QBIOQ BioMed Inc.

About Q BioMed Inc. (QBIO)

Q BioMed Inc. (QBIO) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the Expert Market tier.

Q BioMed Inc. ''Q`` is a biomedical acceleration and development company focused on acquiring companies and biomedical assets in clinical stage or and near revenue development. Q is dedicated to providing these target companies strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Products and services

Q BioMed is a biotechnology company that is advancing several drugs through clinical development. The Company has one commercially available product - Strontium89 Chloride USP Injection. Strontium89 is a radionuclide therapy that has been prescribed for nearly 30 years to help alleviate pain caused by bone mets. Strontium89 has been shown to provide lasting relief from painful bone mets with just one injection, regardless of whether your cancer started in the breast, lung, prostate, or anywhere else in the body. For more information please visit www.strontium89.com

QBIO key facts

Ticker symbol

QBIO

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

US

Year of incorporation

2013

Employees

1

Estimated market cap

$14.5K (as of Apr 11, 2025)

Shares outstanding

145,094,531

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Unaudited

Fiscal year end

11/30

Q BioMed Inc. leadership

• Denis Corin — President, Principal Acct. Officer, Principal Fin. Officer, CEO
• William S. Rosenstadt — Chief Legal Officer
• Ari Jatwes — Finance Director

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with Q